Detection of leukocyte adhesion deficiency type 1 in an infant by high-throughput targeted exome sequencing

Leukocyte adhesion deficiency type 1 (LAD-I) characterized by immune-deficiency and leukocytosis is rare in infant patients. A 43-day-old boy with severe leukocytosis, recurrent infections, defective wound healing and hepatosplenomegaly associated with an acquired cytomegalovirus infection. To establish the diagnosis definitively, a high-throughput targeted exome sequencing was performed, which yielded the diagnosis of LAD-I. A homozygous mutation in integrin subunit beta 2 (ITGB2), c.817G>A (p.G273R) was identified. Though LAD-I has been thoroughlystudied, with more than 300 detailed cases and 96 mutations in ITGB2, establishing a definitive diagnosis of LAD-I in infancy is challenging because of the lack of typical clinical presentations. Better understanding the molecular characterization of this disease is necessary to increase awareness and identification of infants with LAD-I.


INTRODUCTION
Leukocyte adhesion deficiency type 1 (LAD-I) [1] (MIM 600065) with an occurrence of 1 in every 100,000 live births is an autosomal recessive leukocyte recruitment deficiency.It is characterized by recurrent bacterial infections, poor wound healing, and delayed umbilical cord separation.Mutations have been found in integrin subunit beta 2 (ITGB2) gene [2] that is located at 21q22.3 (NM_000211), which leads to the associated heterogeneous clinical spectrum of this disorder.
Since some patients with severe forms die of overwhelming infection at a young age, proper, timely diagnoses become very critical.Although the diagnosis of LAD-I is based on typical clinical presentation, combined with laboratory demonstration of leukocytosis and reduction of CD18 expression, the precise molecular characterization is required for diagnosis confirmation.Recently the use of high-throughput targeted exome sequencing (TES) [3] has resulted in faster sample turnaround time and more cost-effective analysis of the causative mutations.
In this paper, we reported a rare case of a 43-day-old boy referred to our facility for severe leukocytosis, who responded poorly to antibiotic therapy, to highlight the importance of molecular testing to definitively establish the diagnosis when LAD-I is suspected.Moreover, the early diagnosis of immunodeficiency is essential for optimal management such as hematopoietic stem cell transplantation (HSCT) and rehabilitation outcomes.

CASE REPORT
The young patient's family is of Chinese Han ethnicity; a male baby, the second neonate of unrelated parents delivered via cesarean section after an uneventful full-term pregnancy.The proband's birth weight was 3000 g.A review of the family history revealed that his older sister had passed away at the age of 3 months of sepsis with no response to various second-line and third-line antimicrobials.The patient's condition was initially observed when he suffered a fever at the age of 25 days after birth; diagnosed then by his neonatologist as systemic inflammatory response syndrome (SIRS) in a local hospital.Laboratory tests revealed leukocytosis with neutrophil predominance [83,550 (10 9 /L), 70.7%] and high C reactive protein (CRP) (69 mg/L).Intravenous (IV) antibiotics therapy (vancomycin combined with meropenem) was started and maintained for 18 days, with a good clinical response.
Five days later, he was referred to our neonatal department because of hyperthermia and marked neutrophilia.Physical examination upon admission reported a well-developed infant, with head circumference of 34 cm and weighing 4140 g.Hepatosplenomegaly was noted, with liver span of 5 cm and spleen 3 cm below costal margin.The levels of serum inflammatory markers [Table 1] were abnormal, but cultures for bacteria and fungi were negative.Further laboratory investigations showed elevated aminotransferase and high cytomegalovirus (CMV) PCR titers in his urine (positive) and plasma (3.9*10 4 copies/mL) samples.
After receiving the treatment of intravenous immunoglobulin (IVIG), second-line and third-line antimicrobials in the form of cefepime, teicoplanin teiculine and cephalosporins and IV ganciclovir (10 mg/kg/d for 14 days and 5 mg/kg/d for 7 days), he was discharged after three weeks with no fever, declined white cell count and CMV titers and normal liver function.He continued to receive oral ganciclovir (5 mg/kg/d) treatment after discharge.
From then on the patient experienced recurrent upper respiratory tract infections and was admitted to our hospital with two episodes of deep infections coupled with hyperthermia and marked neutrophilia [Table 1].At 2 months of age, a 2.5 cm × 3 cm erythematous skin area surrounding the umbilicus without pus or foul odors and tenderness to palpation around the umbilicus was noted.The ultrasound of the umbilical cord showed an infected urachus.The patient was treated with surgery debridement and resection of his urachus.At the same time, he received IV cefatriaxone, teicoplanin and ganciclovir (5 mg/kg/d).Five days later, his umbilicus had nearly returned to normal.He completed 20 days of antibiotic therapy before and after his surgery.At 4 months of age, he developed bronchopneumonia and showed neutrophilia with elevated CRP [Table 1].Empiric antibiotic therapy was started after his admission and adjusted in form of cefmetazole, cefepime, tienam, meropenem, linezolid, fluconazole and teicoplanin based on those infection indexes.He was treated with IVIG again and IV ganciclovir (5 mg/kg/d) for 2 weeks.He recovered from his cough soon after; his body temperature fluctuated from 37.5 to 38.5 °C and it returned to normal after 3 weeks, then the patient was discharged with liver span of 3 cm, spleen palpable 2 cm below the left costal margin.
Since a thorough history, physical examination, and laboratory workup failed to identify a clear etiology of this extremely abnormal case of leukocytosis, genetic analysis was initiated to find the cause.We performed TES of the immune disease panel (designed by MyGenostics, Beijing, China) on the pedigree.A total of 232 genes associated with defects in neutrophil chemotaxis and phagocytosis were selected using a gene capture strategy with a GenCap custom exome enrichment kit (MyGenostics, Beijing, China).In ITGB2 gene, a previously described mutation c.817G>A (p.G273R) was found in a homozygous state [Figure 1A].This mutation co-segregated with the phenotype in the family.And a pedigree study showed that his father was a carrier of c.817G>A (p.G273R) mutation [Figure 1B], while his mother showed no variant [Figure 1C].Furthermore the same allele was configured by qPCR to eliminate the possibility that his mother had a large fragment deletion involving this position [Figure 1D].
The emergence of next generation sequencing technologies constituted a turning point for the advancement of our understanding of rare diseases including various primary immune-deficiencies which require a broad search for causal variants across their genetically heterogeneous spectrum [5] .And the high throughput TES for specific (known) disease-causing genes has been applied to assist with molecular diagnosis of welldefined disorders caused by a group of genes [6] .
Our patient is characterized by a leukocytosis with neutrophil predominance that never reached normal level after antibiotic treatment [Table 1].We confirmed the diagnosis by genetic testing.c.817G>A in a homozygous form was identified, which resulted in the amino acid substitution Gly273Arg residing in exon 8.This mutation shows nearly no CD18 expression on the leukocyte surface [7] .If it is, 1% of the CD18 expression in normal subjects can be defined as severely deficient patients.The condition is severe and often results in repeated infections in infants and young children, which is consistent with the clinical manifestation of this proband.His father carries heterozygotes for this mutation and his mother is normal of this allele; both parents did not give a history of consanguinity.The lack of consanguinity, as is the characteristic of LAD-I patients, indicated that autosomal recessive inheritance is less likely for this patient, although not excluded.Furthermore, the sole presence of the identified variant in his father revealed that the mutation on the other allele might emerge de novo, although this kind of probability is very low.Based on our pedigree analysis results, loss of heterozygosis [8] might be the most relevant possibility, that the embryo of the proband has undergone a change before its development, leading to two copies of its ITGB2 gene being paternal mutations.
In conclusion, we presented a case of LAD-I associated with acquired CMV infection, an important opportunistic pathogen in patients who are immunocompromised.The genetic investigation helped us to identify the etiology of severe leukocytosis of the patient during his infancy.Following his discharge, further clinical course was marked by successive and progressive infections.The patient was then recommended to another hospital where HSCT is available for immunodeficiency.He was reported to be improving and thriving until now.

Figure 1 .
Figure 1.A: The sequencing exposes a homozygous mutation c.817G>A (p.G273R) in ITGB2 gene in the proband; B: his father carries the mutation; C: his mother does not carry the mutation; D: normal is the control of QPCR for chr21:46320235-46320435, showing that the mother is normal